Creative Touch Permanent Makeup and Aesthetics

Sirtuins are a family of seven NAD⁺-dependent deacetylases (SIRT1–7) that regulate a broad range of cellular processes by removing acetyl groups from specific protein targets. What distinguishes them from other deacetylase classes is their absolute dependence on NAD⁺ as a cosubstrate – consumed, not simply bound – which means sirtuin activity functions as a direct readout of cellular NAD⁺ status. In skin biology, SIRT1 is the most extensively characterised family member, with established roles in circadian clock amplitude maintenance (via BMAL1 deacetylation), NF-κB-mediated inflammation suppression, UV-induced DNA repair (via XPA deacetylation), and dermal fibroblast senescence regulation. SIRT3 and SIRT6 carry distinct but complementary skin roles through mitochondrial ROS management and telomere/genome stability respectively. The family’s central clinical relevance is that no external ingredient or treatment can activate sirtuins in cells where NAD⁺ is depleted – the upstream pool is the constraint, and restoring it is the prerequisite for sirtuin-dependent repair and remodelling to proceed.

Sirtuins are Class III histone deacetylases – but the “histone” classification understates their scope. Their most consequential substrates in skin are non-histone proteins: p53, FOXO transcription factors, the NF-κB subunit p65, the clock protein BMAL1, the DNA repair protein XPA, and the mitochondrial regulator PGC-1α. The deacetylase reaction removes an acetyl group from the target protein’s lysine residue and in doing so consumes one molecule of NAD⁺, releasing nicotinamide and O-acetyl-ADP-ribose as byproducts.

This consumption mechanism is what defines the sirtuin family’s clinical significance. Because NAD⁺ is consumed rather than recycled, sirtuin activity is directly and continuously gated by NAD⁺ pool availability. A cell under metabolic stress, with elevated NADH from substrate overload, or with chronic PARP1 competition for the shared pool, cannot maintain normal sirtuin activity regardless of enzyme expression level. This is developed in full in the NAD⁺ entity; the point for this entity is that any strategy aimed at sirtuin-dependent outcomes in skin must address NAD⁺ sufficiency as its foundation.

The Family: Seven Members, Three Skin-Relevant

Seven sirtuins are expressed in human cells, located in the nucleus, cytoplasm, or mitochondria. Their skin evidence varies considerably:

SIRT1 in Skin

Circadian Clock Regulation

SIRT1 is the molecular link between cellular NAD⁺ status and the precision of the skin’s circadian repair programme. The mechanism was established in two studies that remain the foundational references for this connection.

Nakahata et al. demonstrated that SIRT1 physically associates with the CLOCK-BMAL1 complex and deacetylates BMAL1 – the master transcription factor driving clock gene expression – and that genetic or pharmacological inhibition of SIRT1 produces measurable disruption of circadian gene oscillation. [pubmed.ncbi.nlm.nih.gov/18662547/] Ramsey et al. then established the feedback architecture: BMAL1 and CLOCK drive transcription of NAMPT, the rate-limiting enzyme in NAD⁺ salvage synthesis; NAMPT produces NAD⁺; NAD⁺ activates SIRT1; SIRT1 deacetylates BMAL1 to sustain the next oscillation cycle. ^[6] The clock oscillation and the NAD⁺ salvage cycle are not parallel processes – they are the same loop.

The practical consequence for skin is precise: when NAD⁺ availability falls, SIRT1’s contribution to BMAL1 oscillation amplitude diminishes. The clock continues to run, but with reduced amplitude, meaning the gating of night-time ceramide synthesis, collagen assembly timing, and DNA repair scheduling becomes less precise. This is the cellular mechanism behind what the Metabolic Chronodisruption entity describes at the tissue level.

UV Protection – and a Dual Role That Requires Careful Framing

SIRT1’s protective role in UV-exposed skin operates through two substrates. First, SIRT1 deacetylates XPA (xeroderma pigmentosum complementation group A), a protein essential for nucleotide excision repair – the pathway that removes UV-generated DNA photoproducts (cyclobutane pyrimidine dimers and 6-4 photoproducts). SIRT1 haploinsufficiency in keratinocytes impairs XPC expression and attenuates NER activity, accelerating accumulation of unrepaired UV photodamage. ^[5] Second, SIRT1 deacetylates FOXO3a, reducing ROS-driven apoptosis in lightly damaged cells and allowing the repair machinery time to act before the cell is lost. ^[4]

However, SIRT1’s deacetylation of p53 introduces a nuance that should not be omitted. In cells with repairable DNA damage, suppressing p53-mediated apoptosis is a net benefit – it allows damaged cells to survive long enough for NER to complete repair. The 2017 Tewari et al. study demonstrated that combined UVB and heat stress activates SIRT1 in a way that promotes keratinocyte survival after DNA damage, consistent with this protective framing. ^[3]

The same mechanism becomes a concern if SIRT1 activity is pathologically elevated – or if it operates in cells carrying irreparable mutations – because suppressing p53 in those circumstances allows damaged cells to survive and potentially proliferate. In healthy skin at physiological SIRT1 levels this is managed by the concurrent XPA/XPC repair enhancement. The dual role does not undermine SIRT1’s overall protective function; it means that “more SIRT1 is always better” is not a defensible simplification, and that the relevant clinical goal is restoring depleted SIRT1 function, not artificially amplifying it beyond physiological range.

Anti-Inflammatory Function

SIRT1 deacetylates the p65 subunit of NF-κB at lysine residue 310, reducing NF-κB’s transcriptional activity and thereby suppressing downstream production of TNF-α, IL-6, and IL-1β in dermal fibroblasts. This places SIRT1 in a direct anti- inflammageing role: as NAD⁺ availability falls with age and the SIRT1/NF-κB equilibrium shifts toward deacetylation insufficiency, NF-κB becomes progressively hyperactive, sustaining the chronic low-grade inflammatory environment characteristic of photoaged and intrinsically aged dermis. ^[1]

This mechanism is independent of the clock regulation pathway. A client may experience both clock amplitude loss and NF-κB hyperactivation from the same upstream NAD⁺ depletion – two separate downstream consequences of one shared substrate shortage.

Fibroblast Longevity and Collagen Environment

A 2026 study published in Frontiers in Public Health examined SIRT1’s role in cadmium-exposed dermal fibroblasts as a model for oxidative stress-driven senescence. SIRT1 overexpression in these cells restored redox balance, reduced 8-OHdG accumulation (an oxidative DNA damage marker), preserved mitochondrial morphology, and attenuated SA-β-galactosidase expression – the canonical senescence marker. SIRT1 knockdown produced the opposite phenotype. ^[7] Whilst the cadmium model is not a direct photoageing model, the mechanistic implications are consistent with SIRT1’s established role in managing the oxidative burden that drives fibroblast senescence through UV accumulation, metabolic stress, and chronological ageing.

The clinical significance is that SIRT1 is not simply a clock regulator. It is a gate on fibroblast survival and function – and therefore on the ongoing capacity for collagen synthesis and matrix remodelling that professional treatments depend on stimulating.

Clinical Pearl: The post-treatment collagen response is only as durable as the fibroblast environment sustaining it. A course of RF microneedling or iPRF in a client with chronically suppressed SIRT1 activity – from NAD⁺ depletion, photoageing, or metabolic impasse – activates a fibroblast population that is under ongoing senescence pressure. Homecare that supports NAD⁺ status addresses the underlying environment, not just the surface.

The Fibrosis Caveat

A context-dependent reversal is worth noting for complete accuracy. In fibrotic conditions – particularly systemic sclerosis – SIRT1 activation has been associated with enhanced TGF-β/SMAD signalling and increased pathological collagen production, with SIRT1 knockdown reducing fibrosis in some models. ^[1] This does not change SIRT1’s role in healthy skin, where the same TGF-β engagement supports normal matrix remodelling rather than fibrosis. The distinction is disease-context-specific, but it warrants acknowledgement to avoid the oversimplification that SIRT1 upregulation uniformly improves collagen outcomes across all skin presentations.

Vitiligo and Melanocyte Protection

A 2024 FASEB study identified a Stem Cell Factor-mediated signalling axis that upregulates SIRT1 in vitiligo keratinocytes, reducing UVB-induced oxidative damage in the depigmented keratinocyte environment. ^[2] The implication is that SIRT1 has a role in maintaining the keratinocyte microenvironment that supports melanocyte survival – relevant for perilesional photoprotection strategies and for understanding why oxidative stress management is a component of vitiligo progression rather than merely a comorbidity.

SIRT3 in Skin

SIRT3 is the primary mitochondrial sirtuin, localised to the mitochondrial matrix where it regulates the activity of electron transport chain complexes and deacetylates superoxide dismutase 2 (SOD2), increasing its ROS-scavenging activity. In keratinocytes, where mitochondrial function supports the energy demands of active differentiation and barrier synthesis, SIRT3 activity is the primary enzymatic defence against mitochondrial ROS accumulation.

Reduced SIRT3 activity – via the same NAD⁺ pool depletion that suppresses SIRT1 – correlates with increased mitochondrial superoxide production, which drives oxidative stress-induced senescence and contributes to barrier dysfunction through downstream effects on keratinocyte differentiation capacity. The mechanistic case for SIRT3’s skin relevance is strong and consistent with its well-established role in mitochondrial homeostasis across other tissue types. Direct skin endpoint evidence in human tissue is limited at present.

SIRT6 in Skin

SIRT6 occupies a distinct niche from SIRT1: where SIRT1 regulates dynamic transcriptional and metabolic processes, SIRT6 primarily maintains the structural integrity of chromatin at telomeres and DNA repair sites. It deacetylates histone H3K9 and H3K56 at telomeres, maintaining chromatin compaction and preventing the telomere dysfunction that initiates senescence entry. It also participates in base excision repair, recruiting repair factors to single-strand breaks.

In skin, SIRT6 deficiency accelerates ageing phenotypes in mouse models, with premature fibroblast senescence and impaired wound healing. Its NF-κB suppression activity – operating through a distinct substrate from SIRT1’s p65 mechanism – provides a second independent anti-inflammaging brake. As genomic instability accumulates across cell generations in photoaged skin, SIRT6’s role in telomere maintenance and repair becomes progressively more relevant. Whether SIRT6-specific depletion contributes distinctly to the clinical photoageing phenotype, beyond what SIRT1 depletion alone explains, is an active research question. SIRT6 is flagged as a future independent entity candidate when skin-specific evidence reaches sufficient depth.

Activation, Depletion, and the Resveratrol Correction

What depletes sirtuins: Reduced NAD⁺ availability is the primary and only mechanistically direct suppressor. The routes to depletion – CD38 upregulation in ageing tissue, PARP1 competition from UV damage accumulation, metabolic NADH/NAD⁺ ratio suppression from dietary patterns – are covered in the NAD⁺ entity. Chronological ageing, chronic inflammation, and UV accumulation all converge on NAD⁺ pool reduction as their common downstream mechanism.

What restores sirtuin activity: Precursor-mediated NAD⁺ replenishment. The hierarchy – nicotinamide as the most evidenced option, NMN and NR as mechanistically sound alternatives with emerging human data – is covered in the NAD⁺ page. The practical ceiling is physiological restoration, not supraphysiological amplification.

The resveratrol position. Resveratrol is widely marketed as a “SIRT1 activator” based on a 2003 paper from the Sinclair laboratory reporting direct allosteric activation of SIRT1 in enzyme assays. Subsequent work established that this activation was an artefact of the fluorescent peptide substrate used in the assay – a finding that prompted substantial revision of the direct activation claim. Current evidence indicates that resveratrol’s effects on sirtuin-related outcomes operate indirectly, primarily through AMPK activation leading to NAMPT upregulation and downstream NAD⁺ increase. ^[1] Resveratrol does not activate SIRT1 directly; it may support the NAD⁺ pool that SIRT1 depends on, through a more circuitous metabolic route than its marketing typically describes. The clinical significance is modest either way, and the evidence for resveratrol as a skin-specific intervention at cosmetic concentrations does not approach the level achieved by nicotinamide.